Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun;19(23):e2206948.
doi: 10.1002/smll.202206948. Epub 2023 Mar 6.

Oncolytic Virus-Driven Biotherapies from Bench to Bedside

Affiliations
Review

Oncolytic Virus-Driven Biotherapies from Bench to Bedside

Shijie Duan et al. Small. 2023 Jun.

Abstract

With advances in cancer biology and an ever-deepening understanding of molecular virology, oncolytic virus (OV)-driven therapies have developed rapidly and become a promising alternative to traditional cancer therapies. In recent years, satisfactory results for oncolytic virus therapy (OVT) are achieved at both the cellular and organismal levels, and efforts are being increasingly directed toward clinical trials. Unfortunately, OVT remains ineffective in these trials, especially when performed using only a single OV reagent. In contrast, integrated approaches, such as using immunotherapy, chemotherapy, or radiotherapy, alongside OVT have demonstrated considerable efficacy. The challenges of OVT in clinical efficacy include the restricted scope of intratumoral injections and poor targeting of intravenous administration. Further optimization of OVT delivery is needed before OVs become a viable therapy for tumor treatment. In this review, the development process and antitumor mechanisms of OVs are introduced. The advances in OVT delivery routes to provide perspectives and directions for the improvement of OVT delivery are highlighted. This review also discusses the advantages and limitations of OVT monotherapy and combination therapy through the lens of recent clinical trials and aims to chart a course toward safer and more effective OVT strategies.

Keywords: antitumor mechanisms; clinical trials; intravenous administration; oncolytic viruses; traditional cancer therapies.

PubMed Disclaimer

Similar articles

Cited by

References

    1. R. L. Siegel, K. D. Miller, H. E. Fuchs, A. Jemal, CA Cancer J. Clin. 2021, 71, 7.
    1. M. G. Lizio, R. Boitor, I. Notingher, Analyst 2021, 146, 3799.
    1. C. Y. Chen, Y. S. Lin, C. H. Chen, Y. J. Chen, J. Biomed. Sci. 2018, 25, 30.
    1. H. L. Kaufman, F. J. Kohlhapp, A. Zloza, Nat. Rev. Drug Discovery 2015, 14, 642.
    1. A. H. Choi, M. P. O'Leary, Y. Fong, N. G. Chen, Biomedicines 2016, 4, 18.

Publication types

LinkOut - more resources